Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.
Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients.
Based on its pre-clinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
February 22, 2024
RegMed Investors (RMi) Closing Bell: will the “elevation” trend stay a friend?
February 21, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy equities closes barely positive
February 20, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy equities falter, led by Nasdaq
February 16, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy closed barely positive after a bumpy session
February 15, 2024
RegMed Investors (RMi) Closing Bell: riding the bull
February 14, 2024
RegMed Investors (RMi) Closing Bell: yippee-kai-yay
February 9, 2024
RegMed Investors (RMi) Closing Bell: hang-on to reward prospects for a while
February 8, 2024
RegMed Investors (RMi) Closing Bell: share prices rides on the sector’s merry-go-round
February 7, 2024
RegMed Investors (RMi) Closing Bell: The RegMed sector was stuck with sentiment diarrhea
January 24, 2024
RegMed Investors’ (RMi) pre-open: a number of upsiders are stretched
35 companies, 1 interpreter!
Insight, foresight and recommendation
Biostage (BSTG) - The implementation of this reverse stock split will continue CEO McGorry’s “abuse and destruction of the shareholder value due to his mismanagement, misdirection and misdeeds”. It’s all about salary and “bennies” continuance, violations of fiduciary omittance and having condoned and ignored employee – male and female harassment.” And if that isn’t enough … Is Biostage (BSTG) a Ponzi or Pyramid scheme or a combination of both …? A $300 K down payment and $4 M buys a shell from which $30 M was wasted and a $47 M deficit created …
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors